Angiotensin receptor blockers: therapeutic targets and cardiovascular protection

Area of Science:

• Pharmacology
• Cardiovascular Medicine
• Nephrology

Background:

• Cardiovascular disease (CVD) management requires pharmacotherapy to prevent disease, manage target organ damage (TOD), and prevent events.
• Inhibiting the renin-angiotensin system (RAS) is a successful strategy in cardiovascular and renal medicine.
• Angiotensin-converting enzyme (ACE) inhibitors are established treatments for heart failure, post-myocardial infarction, left ventricular dysfunction, and renal disease.

Purpose of the Study:

• To evaluate the role of ACE inhibitors and angiotensin AT1 receptor blockers (ARBs) in cardiovascular disease prevention and treatment.
• To compare the efficacy and tolerability of ACE inhibitors and ARBs.
• To explore the potential benefits of combining ACE inhibitors and ARBs.

Main Methods:

• Review of existing pharmacological treatment strategies for cardiovascular disease.
• Analysis of the mechanisms of action for ACE inhibitors and ARBs in blocking the renin-angiotensin system.
• Evaluation of clinical evidence regarding the cardiovascular protection, tolerability, and compliance associated with these drug classes.

Main Results:

• ACE inhibitors offer significant advantages over conventional agents but may have tolerability issues.
• Angiotensin AT1 receptor blockers (ARBs) provide an alternative RAS blockade with evidence of additional cardiovascular protection in certain patient groups.
• ARBs generally exhibit better tolerability than ACE inhibitors, improving patient compliance and adherence to long-term therapy.

Conclusions:

• Both ACE inhibitors and ARBs are vital in managing cardiovascular and renal conditions.
• ARBs present a well-tolerated alternative and potential adjunct to ACE inhibitors, enhancing cardiovascular protection.
• Growing evidence supports the combined use of ACE inhibitors and ARBs in specific clinical scenarios for improved patient outcomes.